AI Immune Profiling on Histopathology Slides in Rectal Cancer

Key Takeaways

• TIL positivity was associated with longer disease-free and overall survival, while TAM positivity was associated with shorter disease-free survival in the main cohort.
• Similar directional patterns were described across the additional cohorts.
• The authors also reported KRAS- and TP53-stratified associations, pre- and post-chemoradiotherapy immune shifts, and a possible clinical role for the profiling approach.

They linked these slide-derived measures with disease-free and overall survival across multiple patient datasets. The work emphasized immune and proliferative patterns visible on digitized tissue sections rather than clinical variables alone, and was presented as a multi-cohort evaluation of slide-derived immune and mitotic features.

The analysis included three cohorts: ARISTOTLE-RC, UCLH-RC, and TCGA-CRC. Cases were stratified by AI-quantified densities of tumor-infiltrating lymphocytes, tumor-associated macrophages, and mitotic figures, with cutoffs derived on a hold-out subset. These slide-based features were then combined with DNA mutation data to examine disease-free and overall survival. The abstract does not report sample size or further methodological detail, but these cohorts provided the framework for the outcome analyses described.

Within ARISTOTLE-RC, TIL-positive status was associated with improved disease-free and overall survival, while TAM-positive status was associated with shorter disease-free survival. Investigators described similar directional patterns in UCLH-RC and TCGA-CRC, aligning the reported associations across trial and real-world-style cohorts.

The authors also reported subgroup and transition findings alongside the cohort-level associations. TIL-positive, KRAS-wild-type patients were reported to have improved disease-free and overall survival. Among TP53-mutated tumors, TAM positivity was associated with shorter disease-free survival, while no disease-free survival difference was reported between TAM subgroups in TP53-wild-type disease. Patients who shifted from TIL-negative before treatment to TIL-positive after chemoradiotherapy were also reported to have improved disease-free survival and a higher pretreatment mitotic index, adding further stratification within the analysis.

The investigators interpret the overall pattern of associations as consistent with potential utility for AI-driven immune profiling in this setting. They situate the work within the tumor-immune microenvironment, which they note has an unclear relationship with outcomes after neoadjuvant chemoradiotherapy. Their interpretation remains focused on how slide-derived immune and mitotic features tracked with reported outcomes across the included cohorts. The authors conclude that AI-driven immune profiling may have potential utility in locally advanced rectal cancer.